Author

T. H. Wilson

Observed names: T H Wilson, T.H. Wilson

Institution: PAREXEL International (United States)

Observed institutions: Mayo Clinic, GlaxoSmithKline (United Kingdom), Washington University in St. Louis, GlaxoSmithKline (United States), PAREXEL International (United States)

OpenAlex ID: A5110359836

The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study

2009 · E Becher, C G Roehrborn, et al. · Prostate Cancer and Prostatic Diseases · 44

Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH

2008 · B-H Chung, C G Roehrborn, et al. · Prostate Cancer and Prostatic Diseases · 21

Gastrointestinal safety across the albiglutide development programme

2016 · L. A. Leiter, J. M. Mallory, et al. · Diabetes Obesity and Metabolism · 13

Effects of GI198745 (GG745), A Novel 5-alpha Reductase (5AR) Inhibitor, on Dihydro-Testosterone (DHT)

1996 · D.J. Hermann, I.M. Davis, et al. · Clinical Pharmacology & Therapeutics · 4

The predictive value of HGPIN and ASAP for the subsequent diagnosis of prostate cancer in the Reduction by Dutasteride of Cancer Events (REDUCE) study.

2010 · D. G. Bostwick, D. J. Tindall, et al. · Journal of Clinical Oncology

The influence of unscheduled biopsies on prostate cancer detection in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial

2009 · G. L. Andriole, C. Pettaway, et al. · Journal of Clinical Oncology

Works count: 6

Citation count: 82

H-index: 4

I10-index: 3